For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Navigating the way forward to better health outcomes with immunisation
+Practice
In print
Vaccines
Navigating the way forward to better health outcomes with immunisation
Wednesday 14 February 2024, 12:30 AM

The immunisation conference took place at a time of clear skies through which to navigate [Image: Sebastian Knoll on Unsplash]
This article reflects on the key messages from the most recent Aotearoa New Zealand Immunisation Conference
Key actions, Wrap-around health services work best to support communities.
We come in all shapes and sizes – everyone has a right to easy access to vaccines.
“, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Hobbs M, Marek L, Young A, et al. Examining spatial variation for immunisation coverage in pregnant women: A nationwide and geospatial retrospective cohort study in Aotearoa New Zealand. Soc Sci Med 2023;335:116228.
- Montgomerie I, Bird TW, Palmer OR, et al. Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. iScience 2023;26(4):106256.
- Njuguna HN, Yusuf N, Raza AA, et al. Progress toward maternal and neonatal tetanus elimination – worldwide, 2000–2018. MMWR Morb Mortal Wkly Rep 2020;69(17):515–20.
- Pankhurst TE, Buick KH, Lange JL, et al. MAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity. Cell Rep 2023;42(4):112310.
- Phillips A, Jiang Y, Walsh D, et al. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis. Vaccine 2023;41(42):6227–38.